Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 12 de 12
Filter
1.
J Biol Chem ; 287(44): 37434-46, 2012 Oct 26.
Article in English | MEDLINE | ID: mdl-22961987

ABSTRACT

A proliferation-inducing ligand (APRIL), a member of the TNF ligand superfamily with an important role in humoral immunity, is also implicated in several cancers as a prosurvival factor. APRIL binds two different TNF receptors, B cell maturation antigen (BCMA) and transmembrane activator and cylclophilin ligand interactor (TACI), and also interacts independently with heparan sulfate proteoglycans. Because APRIL shares binding of the TNF receptors with B cell activation factor, separating the precise signaling pathways activated by either ligand in a given context has proven quite difficult. In this study, we have used the protein design algorithm FoldX to successfully generate a BCMA-specific variant of APRIL, APRIL-R206E, and two TACI-selective variants, D132F and D132Y. These APRIL variants show selective activity toward their receptors in several in vitro assays. Moreover, we have used these ligands to show that BCMA and TACI have a distinct role in APRIL-induced B cell stimulation. We conclude that these ligands are useful tools for studying APRIL biology in the context of individual receptor activation.


Subject(s)
Mutant Proteins/chemistry , Tumor Necrosis Factor Ligand Superfamily Member 13/chemistry , Tumor Necrosis Factor Ligand Superfamily Member 13/genetics , Amino Acid Motifs , Amino Acid Sequence , Amino Acid Substitution , Animals , B-Cell Maturation Antigen , B-Lymphocytes/metabolism , B-Lymphocytes/physiology , Cell Survival , Crystallography, X-Ray , HEK293 Cells , Humans , Hydrogen Bonding , Immunoglobulin A/biosynthesis , Mice , Models, Molecular , Molecular Sequence Data , Mutagenesis, Site-Directed , Protein Binding , Protein Structure, Tertiary , Protein Transport , Transmembrane Activator and CAML Interactor Protein
2.
Trends Mol Med ; 17(9): 494-505, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21724465

ABSTRACT

The tumor necrosis factor (TNF) and TNF receptor (TNFR) superfamilies comprise multidomain proteins with diverse roles in cell activation, proliferation and cell death. These proteins play pivotal roles in the initiation, maintenance and termination of immune responses and have vital roles outside the immune system. The discovery and analysis of diseases associated with mutations in these families has revealed crucial mechanistic details of their normal functions. This review focuses on mutations causing four different diseases, which represent distinct pathological mechanisms that can exist within these superfamilies: autoimmune lymphoproliferative syndrome (ALPS; FAS mutations), common variable immunodeficiency (CVID; TACI mutations), tumor necrosis factor receptor associated periodic syndrome (TRAPS; TNFR1 mutations) and hypohidrotic ectodermal dysplasia (HED; EDA1/EDAR mutations). In particular, we highlight how mutations have revealed information about normal receptor-ligand function and how such studies might direct new therapeutic approaches.


Subject(s)
Autoimmune Lymphoproliferative Syndrome/genetics , Common Variable Immunodeficiency/genetics , Ectodermal Dysplasia 3, Anhidrotic/genetics , Hereditary Autoinflammatory Diseases/genetics , Receptors, Tumor Necrosis Factor/genetics , Tumor Necrosis Factor-alpha/genetics , Autoimmune Lymphoproliferative Syndrome/metabolism , Common Variable Immunodeficiency/metabolism , Ectodermal Dysplasia 3, Anhidrotic/metabolism , Edar Receptor/genetics , Fever , Hereditary Autoinflammatory Diseases/metabolism , Humans , Multigene Family , Mutation , Receptors, Tumor Necrosis Factor, Type I/genetics , Transmembrane Activator and CAML Interactor Protein/genetics , fas Receptor/genetics
3.
Blood ; 117(25): 6856-65, 2011 Jun 23.
Article in English | MEDLINE | ID: mdl-21543761

ABSTRACT

APRIL (A proliferation-inducing ligand) is a TNF family member that binds two TNF receptor family members, TACI and BCMA. It shares these receptors with the closely related TNF family member, B-cell activating factor (BAFF). Contrary to BAFF, APRIL binds heparan sulfate proteoglycans (HSPGs), which regulates cross-linking of APRIL and efficient signaling. APRIL was originally identified as a growth promoter of solid tumors, and more recent evidence defines APRIL also as an important survival factor in several human B-cell malignancies, such as chronic lymphocytic leukemia (CLL). To target APRIL therapeutically, we developed two anti-human APRIL antibodies (hAPRIL.01A and hAPRIL.03A) that block APRIL binding to BCMA and TACI. Their antagonistic properties are unique when compared with a series of commercially available monoclonal anti-human APRIL antibodies as they prevent in vitro proliferation and IgA production of APRIL-reactive B cells. In addition, they effectively impair the CLL-like phenotype of aging APRIL transgenic mice and, more importantly, block APRIL binding to human B-cell lymphomas and prevent the survival effect induced by APRIL. We therefore conclude that these antibodies have potential for further development as therapeutics to target APRIL-dependent survival in B-cell malignancies.


Subject(s)
Antibodies, Monoclonal/immunology , B-Cell Maturation Antigen/immunology , B-Lymphocytes/immunology , Lymphoma, B-Cell/immunology , Transmembrane Activator and CAML Interactor Protein/immunology , Tumor Necrosis Factor Ligand Superfamily Member 13/immunology , Animals , Antibodies, Monoclonal/therapeutic use , B-Lymphocytes/cytology , Cell Line, Tumor , Cells, Cultured , Female , Humans , Immunoglobulin A/immunology , Lymphoma, B-Cell/drug therapy , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL
4.
Blood ; 117(23): 6162-71, 2011 Jun 09.
Article in English | MEDLINE | ID: mdl-21471524

ABSTRACT

The development and antigen-dependent differentiation of B lymphocytes are orchestrated by an array of growth factors, cytokines, and chemokines that require tight spatiotemporal regulation. Heparan sulfate proteoglycans specifically bind and regulate the bioavailability of soluble protein ligands, but their role in the immune system has remained largely unexplored. Modification of heparan sulfate by glucuronyl C5-epimerase (Glce) controls heparan sulfate-chain flexibility and thereby affects ligand binding. Here we show that Glce deficiency impairs B-cell maturation, resulting in decreased plasma cell numbers and immunoglobulin levels. We demonstrate that C5-epimerase modification of heparan sulfate is critical for binding of a proliferation inducing ligand (APRIL) and that Glce-deficient plasma cells fail to respond to APRIL-mediated survival signals. Our results identify heparan sulfate proteoglycans as novel players in B-cell maturation and differentiation and suggest that heparan sulfate conformation is crucial for recruitment of factors that control plasma cell survival.


Subject(s)
Carbohydrate Epimerases/immunology , Cell Differentiation/immunology , Heparan Sulfate Proteoglycans/immunology , Plasma Cells/immunology , Signal Transduction/immunology , Tumor Necrosis Factor Ligand Superfamily Member 13/immunology , Animals , Carbohydrate Epimerases/genetics , Cell Differentiation/genetics , Cell Survival/genetics , Cell Survival/immunology , Heparan Sulfate Proteoglycans/genetics , Heparan Sulfate Proteoglycans/metabolism , Mice , Mice, Knockout , Plasma Cells/enzymology , Signal Transduction/genetics , Tumor Necrosis Factor Ligand Superfamily Member 13/genetics , Tumor Necrosis Factor Ligand Superfamily Member 13/metabolism
5.
Results Probl Cell Differ ; 49: 161-82, 2009.
Article in English | MEDLINE | ID: mdl-19142624

ABSTRACT

A Proliferation Inducing Ligand (APRIL) was first identified as a cytokine expressed predominantly by tumour tissues and was not found in most normal tissues. The activity of this new cytokine, in terms of its ability to stimulate tumour cell proliferation in vivo, determined the catchy acronym of yet another TNF family cytokine: APRIL. Reports showing an association between APRIL and cancer have since been prolific, in particular, those showing a link with B cell malignancies. Evidence is accumulating that APRIL is also a player in several autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, and Sjoegren's syndrome. However, we now know that APRIL also plays an important role in the immune system and in lymphocyte biology. In this chapter we outline the physiological role of APRIL in immunity and describe what is known regarding the role of APRIL in B cell malignancies and autoimmune disease.


Subject(s)
Autoimmune Diseases/immunology , B-Lymphocytes/immunology , Gene Expression Regulation, Neoplastic/immunology , Neoplasm Proteins/immunology , Neoplasms/immunology , Tumor Necrosis Factor Ligand Superfamily Member 13/immunology , Animals , Autoimmune Diseases/metabolism , Autoimmune Diseases/pathology , B-Lymphocytes/metabolism , B-Lymphocytes/pathology , Cell Proliferation , Humans , Neoplasm Proteins/biosynthesis , Neoplasms/metabolism , Neoplasms/pathology , Tumor Necrosis Factor Ligand Superfamily Member 13/biosynthesis
6.
FASEB J ; 23(5): 1584-95, 2009 May.
Article in English | MEDLINE | ID: mdl-19141538

ABSTRACT

A proliferation-inducing ligand (APRIL) (also known as TALL-2 and TRDL-1) is a member of the tumor necrosis factor (TNF) superfamily that has tumorigenic properties but is also important for the induction of humoral immune responses. APRIL binds two TNF receptors: transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and B-cell maturation antigen (BCMA) as well as heparan sulfate proteoglycans (HSPGs). The aim of this study was to clarify the role of the HSPG interaction in canonical APRIL signaling, because it has been proposed to act as a docking site and also to play a role in direct signaling. In this study, we generated point mutants of soluble APRIL that lack either the capacity to bind HSPGs or TACI and BCMA and then tested the function of these mutants in mouse B-cell assays. In contrast to previous reports, we found that APRIL alone is sufficient to costimulate B-cell proliferation and drive IgA production and does not require artificial antibody cross-linking. We found no evidence that APRIL requires signaling through HSPGs but, notably, were able to show that binding of APRIL to HSPGs is crucial for mediating natural APRIL cross-linking to allow for optimal activation of murine B cells.


Subject(s)
B-Lymphocytes/cytology , Heparan Sulfate Proteoglycans/metabolism , Tumor Necrosis Factor Ligand Superfamily Member 13/genetics , Animals , B-Cell Maturation Antigen/metabolism , B-Lymphocytes/drug effects , B-Lymphocytes/metabolism , Cells, Cultured , Cross-Linking Reagents/metabolism , Humans , Immunoglobulin A/biosynthesis , Leukosialin/immunology , Ligands , Mice , Models, Molecular , Protein Structure, Tertiary , Signal Transduction , Transmembrane Activator and CAML Interactor Protein/physiology , Tumor Necrosis Factor Ligand Superfamily Member 13/metabolism
7.
J Cell Physiol ; 218(1): 1-8, 2009 Jan.
Article in English | MEDLINE | ID: mdl-18726990

ABSTRACT

A proliferation inducing ligand (APRIL or TALL-2 and TRDL-1) was first discovered as a cytokine over-expressed in many transformed cells and with the capacity to stimulate proliferation. APRIL was shown to bind two different receptors of the TNF receptor superfamily: B cell maturation antigen (BCMA) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI), as well as heparan sulphate proteoglycans (HSPGs). APRIL has since been shown to play a physiological role in B cell biology, in particular the survival of plasma B cells in a specialized APRIL-rich niche. However, aberrant expression of APRIL and the subsequent activation of pro-survival pathways, is potentially the driving force for the survival of several B cell malignancies. APRIL has therefore become an important therapeutic target, but many questions regarding its mechanism of action still remain. It is for instance unclear what the exact physiological implications of the APRIL-HSPG interaction could be. Neither do we know the precise signals elicited by APRIL in normal or in malignant cells, and whether blocking these effects could provide real therapeutic gain in cancer patients. In this review we discuss the specific relevance of APRIL for cell survival, in terms of both its physiological role and its role in tumor biology, and highlight some of the key questions that will undoubtedly form the basis of future research in this field.


Subject(s)
Cell Survival/physiology , Tumor Necrosis Factor Ligand Superfamily Member 13/physiology , Animals , B-Cell Maturation Antigen/physiology , B-Lymphocytes/cytology , B-Lymphocytes/physiology , Cell Transformation, Neoplastic , Humans , Mice , Models, Biological , Neoplasms/pathology , Neoplasms/physiopathology , Signal Transduction , Transmembrane Activator and CAML Interactor Protein/physiology
8.
Arthritis Res Ther ; 9(4): 217, 2007.
Article in English | MEDLINE | ID: mdl-17666110

ABSTRACT

TNF receptor-associated periodic syndrome (TRAPS) is a dominantly inherited disease caused by missense mutations in the TNF receptor 1 (TNFR1) gene. Patients suffer from periodic bouts of severe abdominal pain, localised inflammation, migratory rashes, and fever. More than 40 individual mutations have been identified, all of which occur in the extracellular domain of TNFR1. In the present review we discuss new findings describing aberrant trafficking and function of TNFR1 harbouring TRAPS mutations, challenging the hypothesis that TRAPS pathology is driven by defective receptor shedding, and we suggest that TNFR1 might acquire novel functions in the endoplasmic reticulum, distinct from its role as a cell surface receptor. We also describe the clinical manifestations of TRAPS, current treatment regimens, and the widening array of patient mutations.


Subject(s)
Familial Mediterranean Fever/genetics , Mutation, Missense , Protein Folding , Receptors, Tumor Necrosis Factor, Type I/genetics , Endoplasmic Reticulum/genetics , Endoplasmic Reticulum/metabolism , Familial Mediterranean Fever/metabolism , Familial Mediterranean Fever/therapy , Humans , Receptors, Tumor Necrosis Factor, Type I/chemistry , Receptors, Tumor Necrosis Factor, Type I/metabolism , Signal Transduction
9.
Mol Immunol ; 44(1-3): 73-81, 2007 Jan.
Article in English | MEDLINE | ID: mdl-16884774

ABSTRACT

CD59 was first identified as a regulator of the terminal pathway of complement, which acts by binding to the C8/C9 components of the assembling membrane attack complex (MAC), to inhibit formation of the lytic pore. Structurally, CD59 is a small, highly glycosylated, GPI-linked protein, with a wide expression profile. Functionally, the role of CD59 in complement regulation is well-defined but studies have also shown clear evidence for signalling properties, which are linked to its glycophosphatidyl inositol (GPI) anchor and its location within lipid rafts. Cross-linking of CD59 using specific monoclonal antibodies drives both calcium release and activation of lipid-raft associated signalling molecules such as tyrosine kinases. These observations clearly show that CD59 exhibits roles independent of its function as a complement inhibitor. In this review, we examine the progression of research in this area and explore the alternative functions of CD59 that have recently been defined.


Subject(s)
CD59 Antigens/physiology , Animals , B-Lymphocytes/physiology , Bacterial Proteins/physiology , Bacteriocins , CD2 Antigens/physiology , Calreticulin/physiology , Humans , Killer Cells, Natural/physiology , Lipopolysaccharides/pharmacology , Signal Transduction , T-Lymphocytes/physiology
10.
Blood ; 108(4): 1320-7, 2006 Aug 15.
Article in English | MEDLINE | ID: mdl-16684962

ABSTRACT

Tumor necrosis factor (TNF) receptor-associated periodic syndrome (TRAPS) is an autosomal dominant systemic autoinflammatory disease associated with heterozygous mutations in TNF receptor 1 (TNFR1). Here we examined the structural and functional alterations caused by 9 distinct TRAPS-associated TNFR1 mutations in transfected cells and a mouse "knock-in" model of TRAPS. We found that these TNFR1 mutants did not generate soluble versions of the receptor, either through membrane cleavage or in exosomes. Mutant receptors did not bind TNF and failed to function as dominant-negative inhibitors of TNFR1-induced apoptosis. Instead, TRAPS mutant TNFR1 formed abnormal disulfide-linked oligomers that failed to interact with wild-type TNFR1 molecules through the preligand assembly domain (PLAD) that normally governs receptor self-association. TRAPS mutant TNFR1 molecules were retained intracellularly and colocalized with endoplasmic reticulum (ER) markers. The capacity of mutant receptors to spontaneously induce both apoptosis and nuclear factor kappaB (NF-kappaB) activity was reduced. In contrast, the R92Q variant of TNFR1 behaved like the wild-type receptor in all of these assays. The inflammatory phenotype of TRAPS may be due to consequences of mutant TNFR1 protein misfolding and ER retention.


Subject(s)
Endoplasmic Reticulum/genetics , Familial Mediterranean Fever/genetics , Point Mutation , Protein Folding , Receptors, Tumor Necrosis Factor, Type I/genetics , Signal Transduction/genetics , Animals , Apoptosis/genetics , COS Cells , Chlorocebus aethiops , Disease Models, Animal , Endoplasmic Reticulum/metabolism , Familial Mediterranean Fever/metabolism , Humans , Mice , Mice, Transgenic , NF-kappa B/metabolism , Protein Transport/genetics , Receptors, Tumor Necrosis Factor, Type I/metabolism
11.
Cell Res ; 15(6): 430-8, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15987601

ABSTRACT

TRAIL, tumor necrosis factor-related apoptosis-inducing ligand, is a member of the TNF family of proteins. Tumour cells were initially found to have increased sensitivity to TRAIL compared with normal cells, raising hopes that TRAIL would prove useful as an anti-tumor agent. The production of reliable monoclonal antibodies against TRAIL and its receptors that can stain fixed specimens will allow a thorough analysis of their expression on normal and malignant tissues. Here we report the generation of monoclonal antibodies against TRAIL and its four membrane-bound receptors (TR1-4), which have been used to stain a range of normal and malignant cells, as routinely fixed specimens. Low levels of TRAIL expression were found to be limited mostly to smooth muscle in lung and spleen as well as glial cells in the cerebellum and follicular cells in the thyroid. Expression of the TRAIL decoy receptors (TR3 and 4) was not as widespread as indicated by Northern blotting, suggesting that they may be less important for the control of TRAIL cytotoxicity than previously thought. TR1 and TR2 expression increases significantly in a number of malignant tissues, but in some common malignancies their expression was low, or patchy, which may limit the therapeutic role of TRAIL. Taken together, we have a panel of monoclonal antibodies that will allow a better assessment of the normal role of TRAIL and allow assessment of biopsy material, possibly allowing the identification of tumors that may be amenable to TRAIL therapy.


Subject(s)
Membrane Glycoproteins/biosynthesis , Neoplasms/physiopathology , Receptors, Tumor Necrosis Factor/biosynthesis , Tumor Necrosis Factor-alpha/biosynthesis , Antibodies, Monoclonal/biosynthesis , Apoptosis/drug effects , Apoptosis Regulatory Proteins , Female , GPI-Linked Proteins , Humans , Immunohistochemistry/methods , Jurkat Cells , Male , Membrane Glycoproteins/immunology , Neoplasms/pathology , Receptors, TNF-Related Apoptosis-Inducing Ligand , Receptors, Tumor Necrosis Factor/immunology , Receptors, Tumor Necrosis Factor, Member 10c , Staining and Labeling/methods , TNF-Related Apoptosis-Inducing Ligand , Tissue Distribution , Tumor Necrosis Factor Decoy Receptors , Tumor Necrosis Factor-alpha/immunology
12.
Cell Res ; 14(5): 359-72, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15538968

ABSTRACT

Identification of tumour necrosis factor apoptosis inducing ligand (TRAIL), a TNF family ligand, sparked a torrent of research, following an initial observation that it could kill tumour cells, but spare normal cells. Almost a decade after its discovery, and with five known receptors, the true physiological role of TRAIL is still debated and its anti-tumorigenic properties limited by potential toxicity. This review takes a comprehensive look at the story of this enigmatic ligand, addressing its remaining potential as a therapeutic and providing an overview of the TRAIL receptors themselves.


Subject(s)
Membrane Glycoproteins/physiology , Receptors, Tumor Necrosis Factor/physiology , Tumor Necrosis Factor-alpha/physiology , Animals , Apoptosis/drug effects , Apoptosis/physiology , Apoptosis Regulatory Proteins , Humans , Ligands , Membrane Glycoproteins/therapeutic use , Models, Biological , Protein Structure, Tertiary , TNF-Related Apoptosis-Inducing Ligand , Tumor Necrosis Factor-alpha/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...